[A23-04] Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 20.07.2023
Project no.:
A23-04
Commission:
Commission awarded on 26.01.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adult patients with previously untreated chronic lymphocytic leukaemia
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2023-07-20 A G-BA decision was published.